Trial Profile
A 2 PART STUDY IN HEALTHY SUBJECTS: PART A: A MULTIPLE DOSE, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SUPRA-THERAPEUTIC DOSES OF RO4602522; PART B: A MULTIPLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, POSITIVE-CONTROL, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECT OF RO4602522 ON THE QTC INTERVAL
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Sembragiline (Primary) ; Moxifloxacin
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Roche
- 14 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 19 May 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 14 Apr 2014 New trial record